Human Leukocyte Antigen Fairness in Novel T-Cell Receptor Therapies

This Viewpoint explores how human leukocyte antigen (HLA) restrictions limit applicability of T-cell receptor (TCR) therapies in genetically diverse populations and how stakeholders and address the disparities.